Literature DB >> 28689588

Renal Manifestations of Hepatitis C Virus.

Clodoveo Ferri1, Dilia Giuggioli2, Michele Colaci2.   

Abstract

Hepatitis C virus (HCV) is a hepatotropic and lymphotropic virus responsible for hepatic and extrahepatic autoimmune and neoplastic disorders, including renal involvement, which is the consequence of immune-mediated organ damage due to glomerular deposition of immune-complex and/or anti-HCV IgG antibodies and complement. It can appear at any time during the natural history of HCV infection, more often as membranoproliferative glomerulonephritis, alone or in association with other HCV-related disorders. The presence of renal involvement should be investigated in HCV-infected individuals at the first referral and during clinical follow-up.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Cryoglobulinemia; Cryoglobulinemic vasculitis; Glomerulonephritis; Hepatitis C virus; Kidney; Lymphoma; Renal involvement

Mesh:

Substances:

Year:  2017        PMID: 28689588     DOI: 10.1016/j.cld.2017.03.005

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  3 in total

1.  Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.

Authors:  Kati Kaartinen; Sauli Vuoti; Eero Honkanen; Eliisa Löyttyniemi; Ravinder Singh; Martti Färkkilä
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

2.  Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature.

Authors:  Iacopo Gianassi; Marco Allinovi; Leonardo Caroti; Lino Calogero Cirami
Journal:  World J Nephrol       Date:  2019-11-12

Review 3.  Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy.

Authors:  Arkadiusz Urbanowicz; Radosław Zagożdżon; Michał Ciszek
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-11-15       Impact factor: 4.291

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.